Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740792 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study of Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 776
- Enrollment target
- 20
- Study locations
NCT00740792: Completed Phase 3 study of Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals.
NCT00740792 is a Phase 3 study of Seasonal Allergic Rhinitis that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 776 participants, above the 620-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00740792, a Phase 3 study of Seasonal Allergic Rhinitis, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 776 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)
Primary Outcome
change from baseline in 12-hour reflective(how you felt over the previous 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period. The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improvement.
Conditions Studied
Interventions
- DRUG placebo
- DRUG azelastine HCl/fluticasone propionate
- DRUG azelastine Hcl
- DRUG fluticasone propionate
Study Locations (20)
California
- Clinical Research Center - Encinitas
- AABI Associates Medical Group - Fountain Valley
- William Ebbling, MD Inc - Fresno
- Allergy & Asthma Care Center of So. Cal - Long Beach
- Allergy Research Foundation - Los Angeles
- Southern California Research - Mission Viejo
- Allergy Associates Medical Group Inc - San Diego
- Bensch Research Associates - Stockton
Georgia
- Clinical Research Atlanta - Atlanta
- Atlanta Allergy and Asthma Clinic - Stockbridge
- Clinical Research Atlanta - Stockbridge
Colorado
- Storms Clinical Research Institute - Colorado Springs
- Colorado Allergy and Asthma Centers - Denver
Minnesota
- Clinical Reseacrh Institute - Minneapolis
- Clinical Research Institute - Plymouth
Arizona
- Allergy, Asthma and Immunology Associates - Scottsdale
Illinois
- Sneeze, Wheeze and Itch Associates - Normal
Kansas
- Kansas City Allergy and Asthma - Overland Park
Massachusetts
- Northeast Medical Research Associates - North Dartmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 776 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
What the finished NCT00740792 record still lists
NCT00740792 is an interventional study that assigns participants to a tested intervention. The registered 776 participants enrollment target is mid-sized for trials with a published cap, above the 620-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00740792 names 20 study sites across 9 states, led by California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00740792 about?
NCT00740792 is a clinical study titled "A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)
What is the current status of trial NCT00740792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 776 participants. The study started on 2008-08. Estimated completion is 2008-11.
What conditions does trial NCT00740792 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT00740792?
The interventions under investigation include: placebo (DRUG), azelastine HCl/fluticasone propionate (DRUG), azelastine Hcl (DRUG), fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT00740792?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00740792 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00740792's enrollment target sits among peer trials
776 5th of 16 higher than 12 of 16 other Seasonal Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seasonal Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
COMPLETED · Phase 3
-
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06145763 · 776 participants · NA
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT03460769 · 775 participants
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia